PLoS One
2013
Tamara Antonio, Steven R Childers, Richard B Rothman et al.
36 citations
The iboga alkaloids are a class of small molecules defined structurally on the basis of a common ibogamine skeleton, some of which modify opioid withdrawal and drug self-administration in humans and preclinical models. These compounds may represent an innovative approach to neurobiological investigation and development of addiction pharmacotherapy. In particular, the use of the prototypic iboga...
Drug metabolism and disposition: the biological fate of chemicals
June 1, 2002
Wenjiang Zhang, Yamini Ramamoorthy, Rachel F. Tyndale et al.
17 citations
18-Methoxycoronaridine, a newly developed ibogaine analog, has been reported to decrease the self-administration of morphine, cocaine, ethanol, and nicotine. It has also been reported to attenuate naltrexone-precipitated signs of morphine withdrawal. In this study, three metabolites of 18-methoxycoronaridine (18-MC) were separated and identified by high-performance liquid...
Current Medicinal Chemistry - Central Nervous System Agents
August 1, 2001
Upul K. Bandarage, Martin E. Kuehne, Stanley D Glick
8 citations
Ibogaine (1a), one of the psychoactive indole alkaloids found in the root bark of the West African shrub, Tabernanthe iboga, has purported efficacy in treating multiple forms of drug abuse. A single oral treatment with ibogaine or its salts, in the doses of 6 to 19 mg / kg, or a series of four treatments may, respectively, eliminate addictive behavior for up to 6 months or three years In rats,...
Psychopharmacology
October 1, 1998
Stanley D Glick, Isabelle M Maisonneuve, K E Visker et al.
45 citations
Two studies were conducted to assess, in vivo, potential anti-nicotinic effects of the iboga alkaloid ibogaine and its synthetic congener 18-methoxycoronaridine (18-MC). As previously demonstrated for ibogaine, using microdialysis, pretreatment (19h beforehand) with 18-MC (40 mg/kg, i.p.) significantly attenuated nicotine-induced dopamine release in the nucleus accumbens of awake and freely...
Brain Research
August 3, 1998
D Wei, Isabelle M Maisonneuve, Martin E. Kuehne et al.
48 citations
The iboga alkaloid, ibogaine, its metabolite, noribogaine, and the congener, 18-methoxycoronaridine (18-MC) have all been claimed to have anti-addictive properties in animal models, but the mechanisms underlying these effects are unclear. Ibogaine and noribogaine were shown to have affinity for the serotonin transporter, and inhibition of serotonin reuptake has been proposed to be involved in...
European Journal of Pharmacology
October 8, 1997
Isabelle M Maisonneuve, K E Visker, G L Mann et al.
20 citations
The purpose of this study was to clarify the effects of iboga agents on cocaine-induced hyperactivity. Both inhibition and enhancement of cocaine-induced activity by ibogaine have been reported. In the present study, rats were treated with either ibogaine (40 mg/kg, i.p.), noribogaine (40 mg/kg, i.p.), 18-methoxycoronaridine (40 mg/kg, i.p.), or saline, 1 or 19 h prior to the administration of...
Pharmacology, biochemistry, and behavior
October 1, 1997
Amir H Rezvani, David H Overstreet, Y Yang et al.
78 citations
We previously reported that single administration of ibogaine, an indol alkaloid with antiaddictive properties, dose dependently reduced alcohol intake in three strains of alcohol-preferring rats. The present study examined the effect of different doses of a newly developed nontoxic ibogaine analogue, 18-methoxycoronaridine (18-MC), on alcohol intake. Selectively bred alcohol-preferring rats...
European Journal of Pharmacology
August 8, 1996
Richard T. Layer, P Skolnick, C M Bertha et al.
48 citations
Based on both preclinical findings and anecdotal evidence in man, the psychoactive indole alkaloid ibogaine has been suggested to have anti-addictive properties. Previous studies indicate that blockade of NMDA receptors may mediate at least some of the putative anti-addictive actions of ibogaine. The potencies of a series of ibogaine analogs to inhibit...
Brain Research
May 6, 1996
Stanley D Glick, Martin E. Kuehne, Isabelle M Maisonneuve et al.
118 citations
Ibogaine, a naturally occurring iboga alkaloid, has been claimed to be effective in treating addiction to opioids and stimulants, and has been reported to inhibit morphine and cocaine self-administration in rats. However, ibogaine also has acute nonspecific side effects (e.g. tremors, decreased motivated behavior in general) as well as neurotoxic effects (Purkinje cell loss) manifested in the...
European Journal of Pharmacology
June 6, 1995
W D Bowen, B J Vilner, W Williams et al.
95 citations
Ibogaine (12-methoxyibogamine) exhibited moderate affinity for sigma 2 sites (Ki = 201 nM) and low affinity for sigma 1 sites (Ki = 8554 nM), thus showing 43-fold selectivity for sigma 2 receptors. Tabernanthine (13-methoxyibogamine) and (+/-)-ibogamine had sigma 2 Ki = 194 nM and 137 nM, respectively. However, they showed 3- to 5-fold higher sigma 1 affinity compared to ibogaine, resulting in...
Brain Research
September 19, 1994
Stanley D Glick, Martin E. Kuehne, J Raucci et al.
189 citations
Ibogaine, a naturally occurring alkaloid, has been claimed to be effective in treating addiction to opioid and stimulant drugs and has been reported to decrease morphine and cocaine self-administration in rats. The present study sought to determine if other iboga alkaloids, as well as the chemically related harmala alkaloid harmaline, would also reduce the intravenous self-administration of...
Brain Research
February 7, 1992
D C Deecher, M Teitler, D M Soderlund et al.
143 citations
Assays using radioligands were used to assess the actions of ibogaine and harmaline on various receptor types. Ibogaine congeners showed affinity for opiate receptors whereas harmaline and harmine did not. The Ki for coronaridine was 2.0 microM at mu-opiate receptors. The Kis for coronaridine and tabernanthine at the delta-opiate receptors were 8.1 and 3.1 microM, respectively. Ibogaine,...